SCHEMBL5111602

SCHEMBL5111602

O=c1oc2ccc3ccccc3c2c(O)c1-c1cc2c(=O)oc3ccc4ccccc4c3c2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 4/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
AHR P35869 3/20 0.45
CYP3A4 P08684 3/20 0.45
NPC1 O15118 2/20 0.45
PAX8 Q06710 2/20 0.45
MEN1 O00255 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 2/20 0.45
CYP2C19 P33261 2/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
ABCG2 Q9UNQ0 2/20 0.44
CYP1A2 P05177 3/20 0.43
CYP1A1 P04798 2/20 0.43
FYN P06241 1/20 0.43
MAPK3 P27361 1/20 0.43
KDM4E B2RXH2 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5110815 0.77 MAOA (0.43) TDP1L3MBTL1CYP3A4MEN1MAPT
SCHEMBL5111292 0.77 KDM4E (0.50) L3MBTL1CYP3A4MEN1MAPTKMT2A
SCHEMBL5114480 0.76 MAOA (0.40) TDP1L3MBTL1CYP3A4MEN1MAPT
SCHEMBL5124620 0.72 ESR2 (0.46) TDP1CYP3A4NPC1MEN1MAPT
SCHEMBL1619646 0.72 TDP1 (0.70) TDP1L3MBTL1AHRCYP3A4NPC1
SCHEMBL13857102 0.71 NQO1 (0.64) TDP1L3MBTL1CYP3A4MEN1MAPT
SCHEMBL11776616 0.70 TDP1 (0.68) TDP1L3MBTL1AHRCYP3A4NPC1
SCHEMBL5118497 0.70 ESR2 (0.49) CYP3A4NPC1MEN1MAPTKMT2A
SCHEMBL5119584 0.70 ESR1 (0.45) CYP3A4MEN1MAPTKMT2ARAB9A
SCHEMBL5126659 0.70 CLK2 (0.50) TDP1CYP3A4NPC1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US claimed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US claimed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S TDP1 1053/4885L3MBTL1 4632/4885AHR 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.